| 16.16 0.19 (1.19%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.34 | 1-year : | 23.76 |
| Resists | First : | 17.42 | Second : | 20.34 |
| Pivot price | 15.72  |
|||
| Supports | First : | 13.92 | Second : | 11.76 |
| MAs | MA(5) : | 16.48  |
MA(20) : | 15.03 |
| MA(100) : | 14.83 |
MA(250) : | 17.87 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 73.4 |
D(3) : | 80.1 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 26.03 | Low : | 11.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SIBN ] has closed below upper band by 41.5%. Bollinger Bands are 87.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.21 - 16.29 | 16.29 - 16.37 |
| Low: | 15.5 - 15.59 | 15.59 - 15.67 |
| Close: | 16.03 - 16.16 | 16.16 - 16.29 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Thu, 25 Jul 2024
Swiss National Bank Sells 3,400 Shares of SI-BONE, Inc. (NASDAQ:SIBN) - Defense World
Tue, 23 Jul 2024
Champlain Investment Partners LLC Boosts Position in SI-BONE, Inc. (NASDAQ:SIBN) - MarketBeat
Sun, 21 Jul 2024
SI-BONE, Inc. (NASDAQ:SIBN) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Sun, 21 Jul 2024
SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Rating of “Buy” from Analysts - Defense World
Mon, 15 Jul 2024
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024 - StockTitan
Fri, 12 Jul 2024
Insiders Sold US$3.1m Of SI-BONE Stock Possibly Sending Warning Sign - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 101 (%) |
| Shares Short | 2,300 (K) |
| Shares Short P.Month | 2,740 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | -30 % |
| Operating Margin | -31.8 % |
| Return on Assets (ttm) | -16 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | 15.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.49 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -14.97 |
| PEG Ratio | -2 |
| Price to Book value | 4 |
| Price to Sales | 4.62 |
| Price to Cash Flow | -42.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|